Time-Course Transcriptome Analysis for Drug Repositioning in Fusobacterium nucleatum-Infected Human Gingival Fibroblasts

Wenyan Kang, Zhilong Jia, Di Tang, Xiaojing Zhao, Jinlong Shi, Qian Jia, Kunlun He, Qiang FengFrontiers in Cell and Developmental Biology 2019 · DOI

TL;DR

This study uses time-course RNA sequencing to map the dynamic gene expression changes in human gingival fibroblasts (GFs) infected with Fusobacterium nucleatum (F. nucleatum). By analyzing these temporal patterns, the researchers identified key molecular pathways involved in the host response and employed a computational drug repositioning strategy to discover existing drugs that could potentially treat F. nucleatum infections. Six FDA-approved drugs were validated in vitro for their ability to reduce F. nucleatum-induced cellular damage.

What Problem Does This Paper Address?

Fusobacterium nucleatum is a significant pathogen in periodontal disease, contributing to tissue destruction and facilitating the colonization of other harmful bacteria. While its role in oral infections is established, the precise molecular mechanisms by which it interacts with human gingival fibroblasts (GFs) – the primary cellular defense in the gums – and how these interactions evolve over time remain poorly understood. Existing research often relies on static snapshots of infection, missing the dynamic nature of the host-pathogen interplay. Furthermore, effective treatments specifically targeting F. nucleatum-induced damage in GFs are limited. This paper aims to fill this knowledge gap by providing a detailed, time-resolved understanding of the host response and by leveraging computational methods to identify existing drugs that could be repurposed for therapeutic intervention.

Methods

The core of this study involves a multi-pronged approach:

  • Time-Course RNA Sequencing (RNA-seq): GFs were infected with F. nucleatum at various time points (2, 6, 12, 24, and 48 hours) to capture the dynamic changes in gene expression. This allowed for the identification of differentially expressed genes (DEGs) at each stage of infection.
  • Bioinformatic Analysis:
    • Differential Expression Analysis: Standard statistical methods were used to identify genes whose expression levels changed significantly between infected and control groups.
  • Pathway and Gene Ontology (GO) Enrichment Analysis: KEGG pathway and GO analysis were performed on the DEGs to understand the biological functions and signaling pathways that were activated or suppressed during infection. This was done for each time point to observe temporal shifts.
  • Coexpression Analysis (Cogena): A novel computational tool, cogena, was used to group DEGs into clusters based on their coexpression patterns. This approach assumes that coexpressed genes often function coordinately and can be targeted together.
  • Drug Repositioning: The cogena tool was then used to identify FDA-approved drugs that could reverse the gene expression signatures observed in the coexpression clusters. This computational strategy aims to find drugs that can "correct" the cellular response to infection.
  • Biological Validation: Six candidate drugs identified through computational analysis were experimentally validated in vitro. This involved assessing their effects on:
  • Cell Viability: Ensuring the drugs did not harm the GFs at effective concentrations.
  • Reactive Oxygen Species (ROS) Generation: Measuring the reduction of F. nucleatum-induced ROS, a key mediator of cellular damage.
  • Signaling Pathway Activation: Using Western blot analysis to examine the impact of the drugs on key signaling pathways, including AKT, NF-κB, and MAPK, which are known to be involved in inflammation and cell survival.

Datasets

The study generated and analyzed RNA-seq data from human gingival fibroblasts infected with Fusobacterium nucleatum at multiple time points. The raw sequence data has been deposited in the Genome Sequence Archive (BIG Data Center, accession number CRA001739) and the GEO database (accession number GSE118691). No new benchmarks were introduced; rather, existing public databases and computational tools were utilized.

Key Insights and Ideas

  • Dynamic Host Response: The study highlights that the host response to F. nucleatum infection is not static but evolves over time. Early stages (before 12 hours) are characterized by immune-related signaling pathways (e.g., TNF, IL-17, NF-κB), while later stages (after 12 hours) show a shift towards metabolic pathways. This temporal understanding is crucial for developing targeted interventions.
  • Coexpression as a Therapeutic Target: The concept of grouping DEGs into coexpression clusters and then identifying drugs that can reverse these patterns is a powerful strategy. It suggests that targeting coordinated gene networks might be more effective than targeting individual genes.
  • Repurposing Existing Drugs: The successful identification and validation of FDA-approved drugs for a new indication (F. nucleatum infection) demonstrate the value of drug repositioning. This approach significantly reduces the time and cost associated with drug development.
  • Multiple Pathways Involved: F. nucleatum infection impacts several critical cellular pathways, including those involved in inflammation (NF-κB, MAPK) and cell survival/proliferation (AKT). The validated drugs show efficacy in modulating these pathways.

Key Results

  • DEGs Over Time: The number of differentially expressed genes increased significantly with infection time, from 79 at 2 hours to 707 at 48 hours.
  • Temporal Pathway Activation: Immune-related pathways were enriched early, while metabolic pathways were enriched later.
  • Drug Repositioning Success: A computational approach identified several candidate drugs. Six drugs – etravirine, zalcitabine, wortmannin, calcium D-pantothenate, ellipticine, and tanespimycin – were experimentally validated.
  • Inhibition of ROS: All six validated drugs significantly reduced F. nucleatum-induced intracellular ROS generation.
  • Modulation of Signaling Pathways: The drugs demonstrated varying degrees of effectiveness in blocking F. nucleatum-activated AKT, MAPK (ERK, JNK, p38), and NF-κB signaling pathways. Tanespimycin, in particular, showed strong inhibition of NF-κB signaling.

Limitations and Future Work

  • In Vitro vs. In Vivo: The study's biological validation was conducted in vitro. The authors acknowledge that comprehensive in vivo validation is necessary to fully assess the therapeutic potential of these drugs in animal models.
  • Drug Combinations: The study suggests that single drugs may not fully reverse the inflammatory response induced by F. nucleatum, hinting that combination therapy might be more effective. This is a promising avenue for future research.
  • Detailed Biological Effects: While the study validated effects on ROS and key signaling pathways, further comprehensive validation of each drug's biological effects on GF properties (proliferation, apoptosis, migration, differentiation) is recommended.
  • Mechanism of Action: While the drugs were shown to modulate specific pathways, a deeper dive into the precise molecular mechanisms by which each drug exerts its protective effect against F. nucleatum infection could be beneficial.

Summary updated

Abstract

<i>Fusobacterium nucleatum</i> (<i>F. nucleatum</i>) is a crucial periodontal pathogen and human gingival fibroblasts (GFs) are the first line of defense against oral pathogens. However, the research on potential molecular mechanisms of host defense and effective treatment of <i>F. nucleatum</i> infection in GFs remains scarce. In this study, we undertook a time-series experiment and performed an RNA-seq analysis to explore gene expression profiles during the process of <i>F. nucleatum</i> infection in GFs. Differentially expressed genes (DEGs) could be divided into three coexpression clusters. Functional analysis revealed that the immune-related signaling pathways were more overrepresented at the early stage, while metabolic pathways were mainly enriched at the late stage. We computationally identified several U.S. Food and Drug Administration (FDA)-approved drugs that could protect the <i>F. nucleatum</i> infected GFs via a coexpression-based drug repositioning approach. Biologically, we confirmed that six drugs (etravirine, zalcitabine, wortmannin, calcium D-pantothenate, ellipticine, and tanespimycin) could significantly decrease <i>F. nucleatum</i>-induced reactive oxygen species (ROS) generation and block the Protein Kinase B (PKB/AKT)/mitogen-activated protein kinase signaling pathways. Our study provides more detailed molecular mechanisms of the process by which <i>F. nucleatum</i> infects GFs and illustrates the value of the cogena-based drug repositioning method and the potential therapeutic application of these tested drugs in the treatment of <i>F. nucleatum</i> infection.
BibTeX
@inproceedings{kang2019time,
  author = {Wenyan Kang and Zhilong Jia and Di Tang and Xiaojing Zhao and Jinlong Shi and Qian Jia and Kunlun He and Qiang Feng},
  title = {{Time-Course Transcriptome Analysis for Drug Repositioning in Fusobacterium nucleatum-Infected Human Gingival Fibroblasts}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2019},
  doi = {10.3389/fcell.2019.00204},
}
Figure